Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.
Economic releases and corporate results feed directly into rate expectations, currency moves and equity pricing, so the detail here often matters more to markets than the headline itself.
When each newsroom published on this story, oldest first — all times UTC.
Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production
The original report was published by CNBC. WorldPing does not claim that reporting — this page summarises and contextualises it.
Read the full report at CNBC
WorldPingAs the first sitting president visit to Gracie Mansion in decades, Trump backsed mayor's Sunnyside Yards push.
Brief by WorldPing · Original reporting by Fortune
WorldPingLarge network balances sit alongside uneven ETF flows, while the benefit to ETH holders depends on purchases and fees.
Brief by WorldPing · Original reporting by CryptoSlate
WorldPingThe fall equinox, which arrives Tuesday in the U.S., brings shorter days, and chances to witness alignment between Earth and the sun. It's a modern version of ancient observances of a celestial shift.
Brief by WorldPing · Original reporting by NPR Top
WorldPingThe latest addition to X's Under the Hood feature could stave off claims around shadowbanning.
Brief by WorldPing · Original reporting by Engadget
They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.
Brief by WorldPing · Original reporting by CNBC World
WorldPingShares in Grail, the company developing a blood test for cancer, surged Monday after the FDA posted documents ahead of an advisory committee meeting.
Brief by WorldPing · Original reporting by STAT
WorldPing